BioMedNewsBreaks – Why PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’
PaxMedica (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself. PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions,” a recent article reads. “PaxMedica’s lead programs, PAX-101 and PAX-102, utilize…